Menu

Former Wayne State Cancer Researcher Lodges 19th Retraction

Fazlul Sarkar had unsuccessfully sued PubPeer to reveal the identity of a commenter who accused him of research misconduct.

Jan 2, 2018
Shawna Williams

PIXABAY, DELPHINMEDIAA cancer researcher formerly found by a Wayne State University investigative committee to have engaged in research misconduct has racked up his 19th paper retraction, Retraction Watch reports. The retired pathologist, Fazlul Sarkar, had gained notoriety both for the investigation’s results and for his unsuccessful 2016 lawsuit against PubPeer, which sought to force the online discussion site to reveal the identity of commenters who alleged misconduct on his part.

See “PubPeer Wins Appeal on Anonymous Comments

The new retraction, dated December 22, is of a 2012 study in Cancer Letters titled “Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells.” The retraction notice explains that the Wayne State investigation found a discrepancy between the originally collected data and those reported in two of the paper’s figures.

The 2015 Wayne State report recommended that 42 of Sarkar’s papers be retracted—of those, more than half remain intact, Retraction Watch notes.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.